US stock · Healthcare sector · Biotechnology
A
Adicet Bio, Inc.
ACET
NASDAQ5.89
USD
+0.10
(+1.73%)
Market Closed
-5.81P/E
-2Forward P/E
-0.28P/E to S&P500
253.005MMarket CAP
- -Div Yield
Upcoming Earnings
10 May-15 May
Shares Short
3/15/23
3.04M
Short % of Float
9.46%
Short % of Shares Outs.
7.07%
% Held by Insiders
4.82%
% Held by Institutions
104.85%
Beta
2.02
PEG Ratio
-0.07
52w. high/low
21.87/5.64
Avg. Daily Volume
0.53M
Return %
Stock
S&P 500
1 year
(41.17)
(9.05)
3 years
4.46
50.26
5 years
1.18
38.50
Scale: |
High
Low
11.04
5.80
11.70
4.80
9.23
4.88
9.47
4.51
10.20
6.56
25.24
9.60
25.25
16.52
32.20
18.03
26.90
15.69
22.43
8.29
11.98
0.79
83.72
0.13
21.70
6.02
17.80
6.25
21.87
7.56
9.53
6.82
Currency: USD
- -
- -
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
- -
- -
14.77
13.18
13.88
15.92
16.71
18.47
18.47
18.22
19.04
19.19
0.42
0.05
2.45
1.33
0.80
Earnings per share
- -
- -
0.55
0.35
0.26
0.35
0.64
0.83
0.83
1.04
1.17
1.19
(0.47)
(1.44)
(5.01)
(8.47)
(1.44)
FCF per share
- -
- -
0.58
0.90
(0.78)
0.33
0.43
0.78
0.85
0.83
0.21
0.67
(0.97)
(1.48)
(5.81)
- -
(0.93)
Dividends per share
- -
- -
- -
0.20
0.20
0.20
0.20
0.22
0.22
0.24
0.24
0.24
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
0.05
0.02
0.16
0.21
0.04
0.04
0.04
0.04
0.02
0.04
0.04
0.05
0.14
- -
0.26
Book Value per sh.
- -
- -
- -
5.73
5.67
5.39
6.05
6.21
7.20
8.34
8.85
10.46
20.68
(3.08)
15.00
41.41
7.88
Comm.Shares outs.
- -
- -
24
24
25
26
27
27
27
28
29
29
20
20
7
7
39
Avg. annual P/E ratio
- -
- -
14.0
19.0
24.6
20.0
13.9
17.3
24.2
23.2
18.5
11.9
(9.4)
(26.9)
(2.6)
(1.4)
(5.8)
P/E to S&P500
- -
- -
0.7
0.3
1.2
1.2
0.9
1.0
1.3
1.2
0.8
0.5
(0.4)
(1.1)
(0.1)
(0.0)
(0.3)
Avg. annual div. yield
- -
- -
- -
3.0%
3.1%
2.9%
2.3%
1.6%
1.1%
1.0%
1.1%
1.7%
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
360
323
347
412
444
500
500
510
547
559
8
1
18
10
31
Operating margin
- -
- -
5.9%
3.7%
2.7%
4.0%
5.7%
6.9%
6.9%
8.7%
10.3%
10.4%
(182.9)%
(3,154.6)%
(218.9)%
(631.4)%
(Infinity)%
Depreciation (m)
- -
- -
2
2
3
6
7
7
7
8
12
16
1
1
1
- -
2
Net profit (m)
- -
- -
13
9
7
9
17
22
22
29
33
35
(9)
(28)
(37)
(62)
(56)
Income tax rate
- -
- -
39.3%
32.2%
35.5%
47.1%
31.4%
35.4%
35.4%
35.1%
37.8%
35.4%
6.0%
(0.1)%
7.1%
0.2%
0.0%
Net profit margin
- -
- -
3.7%
2.7%
1.9%
2.2%
3.8%
4.5%
4.5%
5.7%
6.1%
6.2%
(113.7)%
(2,827.9)%
(204.9)%
(637.2)%
(Infinity)%
Working capital (m)
- -
- -
- -
129
125
121
115
118
128
158
185
254
249
49
78
266
269
Long-term debt (m)
- -
- -
- -
20
21
34
6
39
20
97
100
119
339
- -
- -
19
19
Equity (m)
- -
- -
- -
140
142
140
161
168
195
234
254
304
405
(60)
110
303
318
ROIC
- -
- -
- -
5.5%
4.2%
6.2%
8.2%
10.5%
10.1%
8.7%
9.9%
8.9%
(1.1)%
(42.2)%
(27.8)%
(19.3)%
(16.6)%
Return on capital
- -
- -
- -
5.8%
5.1%
8.0%
8.8%
12.3%
11.3%
10.0%
11.8%
11.3%
(1.0)%
(34.5)%
(25.6)%
(18.4)%
(15.8)%
Return on equity
- -
- -
- -
6.1%
4.6%
6.4%
10.6%
13.3%
11.5%
12.4%
13.2%
11.4%
(2.3)%
46.6%
(33.4)%
(20.5)%
(17.5)%
Plowback ratio
- -
- -
100.0%
42.6%
23.0%
41.9%
68.6%
73.1%
73.1%
76.5%
79.2%
79.6%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
22.5%
(26.0)%
60.4%
263.8%
185.1%
213.1%
176.2%
1,197.5%
322.6%
- -
- -
- -
- -
- -
Capital Structure
8 Nov · 2022 | Q3
All numbers in millions
Total liabilities
$ 37
Total assets
$ 354
Long-term debt
$ 19
Cash and equiv.
$ 283
Goodwill
$ 19
Retained earnings
$ (208)
Common stock
42
Enterprise Value
$ (10)
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
62
95
278
Receivables
1
3
0
Inventory
- -
- -
- -
Other
1
77
272
Current assets
64
100
282
Acc. Payable
1
2
3
Debt due
- -
1
2
Other
14
20
11
Current liabilities
15
22
16
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(45.65)%
366.82%
165.68%
Cash flow
- -
- -
- -
Earnings
69.04%
43.81%
28.43%
Dividends
- -
- -
- -
Book value
176.01%
(46.94)%
(13.21)%
Insider Trading
Type
Shares
Date
Healey Don
Sale
4,533
02/15/23
Healey Don
Sale
10,467
02/10/23
Schor Chen
Award
384,900
01/24/23
Schor Chen
Award
85,500
01/24/23
Aftab Blake
Award
117,200
01/24/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
2
7
3
5
18
2021
(4)
5
3
6
10
2022
25
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(0.61)
(1.16)
(2.02)
(1.22)
(5.01)
2021
(2.91)
(1.48)
(1.91)
(2.16)
(8.47)
2022
0.12
(0.56)
(0.53)
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA
Full-time employees:
86
City:
Boston
Address:
200 Clarendon Street
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Recent News
· 6 Dec, 2021 · The Wall Street Journal